Viviana A Simon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5466459/publications.pdf

Version: 2024-02-01

134 papers	17,917 citations	31902 53 h-index	18075 120 g-index
167 all docs	167 docs citations	167 times ranked	26572 citing authors

#	Article	IF	Citations
1	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, 371, .	6.0	2,268
2	A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine, 2020, 26, 1033-1036.	15.2	1,678
3	Identification of microRNAs of the herpesvirus family. Nature Methods, 2005, 2, 269-276.	9.0	1,073
4	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science, 2020, 370, 1227-1230.	6.0	1,035
5	SARSâ€CoVâ€2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Current Protocols in Microbiology, 2020, 57, e100.	6.5	670
6	Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New England Journal of Medicine, 2021, 384, 1372-1374.	13.9	659
7	HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet, The, 2006, 368, 489-504.	6.3	496
8	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	13.7	475
9	DENV Inhibits Type I IFN Production in Infected Cells by Cleaving Human STING. PLoS Pathogens, 2012, 8, e1002934.	2.1	411
10	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, 2022, 602, 682-688.	13.7	395
11	Introductions and early spread of SARS-CoV-2 in the New York City area. Science, 2020, 369, 297-301.	6.0	356
12	SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe, The, 2021, 2, e283-e284.	3.4	344
13	Serology assays to manage COVID-19. Science, 2020, 368, 1060-1061.	6.0	306
14	Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nature Microbiology, 2017, 2, 17037.	5.9	292
15	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell, 2021, 184, 3936-3948.e10.	13.5	241
16	Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nature Immunology, 2015, 16, 546-553.	7.0	238
17	Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification. PLoS Pathogens, 2005, 1, e6.	2.1	226
18	SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-GoutiÃ¨res Syndrome Are Highly Susceptible to HIV-1 Infection. PLoS Pathogens, 2011, 7, e1002425.	2.1	225

#	Article	IF	Citations
19	Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5777-5782.	3.3	213
20	Dengue Virus Co-opts UBR4 to Degrade STAT2 and Antagonize Type I Interferon Signaling. PLoS Pathogens, 2013, 9, e1003265.	2.1	188
21	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 2021, 39, 1028-1030.	7.7	176
22	Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 439-446.	0.9	175
23	A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. Cell Reports, 2016, 17, 1438-1452.	2.9	167
24	An In Vitro Microneutralization Assay for SARSâ€CoVâ€2 Serology and Drug Screening. Current Protocols in Microbiology, 2020, 58, e108.	6.5	165
25	Cytidine deamination induced HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5501-5506.	3.3	148
26	Polymorphisms and Splice Variants Influence the Antiretroviral Activity of Human APOBEC3H. Journal of Virology, 2009, 83, 295-303.	1.5	138
27	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host and Microbe, 2022, 30, 373-387.e7.	5.1	138
28	Origin of the HIV-1 group O epidemic in western lowland gorillas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1343-52.	3.3	136
29	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe, The, 2020, 1, e283-e289.	3.4	133
30	HIV-1 dynamics in vivo: implications for therapy. Nature Reviews Microbiology, 2003, 1, 181-190.	13.6	130
31	Discontinuation of Antiretroviral Therapy Commenced Early during the Course of Human Immunodeficiency Virus Type 1 Infection, with or without Adjunctive Vaccination. Journal of Infectious Diseases, 2002, 186, 634-643.	1.9	129
32	Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature, 2021, 590, 146-150.	13.7	128
33	BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host and Microbe, 2015, 18, 345-353.	5.1	124
34	HIV-1 Vpu Antagonism of Tetherin Inhibits Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells. Journal of Virology, 2014, 88, 6031-6046.	1.5	118
35	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
36	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	1.9	116

#	Article	IF	Citations
37	Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. Immunity, 2016, 44, 46-58.	6.6	110
38	Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. Aids, 2002, 16, 1511-1519.	1.0	109
39	Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 33-37.	0.9	103
40	HIV-1 Vif Adaptation to Human APOBEC3H Haplotypes. Cell Host and Microbe, 2013, 14, 411-421.	5.1	92
41	The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. Journal of Virology, 2012, 86, 49-59.	1.5	88
42	A Doubly Fluorescent HIV-1 Reporter Shows that the Majority of Integrated HIV-1 Is Latent Shortly after Infection. Journal of Virology, 2013, 87, 4716-4727.	1.5	88
43	Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications, 2018, 9, 4560.	5.8	88
44	Determining the Relative Efficacy of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2003, 187, 896-900.	1.9	85
45	APOBEC3A, APOBEC3B, and APOBEC3H Haplotype 2 Restrict Human T-Lymphotropic Virus Type 1. Journal of Virology, 2012, 86, 6097-6108.	1.5	84
46	Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology, 2006, 352, 169-177.	1.1	79
47	Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. Aids, 2003, 17, 1151-1156.	1.0	77
48	Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. Cell Host and Microbe, 2020, 28, 614-627.e6.	5.1	76
49	Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2004, 78, 10566-10573.	1.5	68
50	Vif Proteins of Human and Simian Immunodeficiency Viruses Require Cellular CBFÎ² To Degrade APOBEC3 Restriction Factors. Journal of Virology, 2012, 86, 2874-2877.	1.5	65
51	Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure. Journal of Virology, 2002, 76, 7000-7009.	1.5	63
52	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	7.7	62
53	APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host. PLoS Pathogens, 2013, 9, e1003641.	2.1	59
54	SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine, 2021, 68, 103401.	2.7	58

#	Article	IF	Citations
55	Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface. Cell Reports, 2015, 13, 1789-1799.	2.9	57
56	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, 0, , .	13.7	56
57	Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection. Journal of Virology, 2003, 77, 7736-7745.	1.5	55
58	Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids, 2010, 24, 2313-2321.	1.0	53
59	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. Journal of Clinical Investigation, 2018, 128, 4992-4996.	3.9	51
60	COVID-19: Staging of a New Disease. Cancer Cell, 2020, 38, 594-597.	7.7	48
61	Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. Immunity, 2020, 53, 852-863.e7.	6.6	46
62	HIV-1 Interacts with Human Endogenous Retrovirus K (HML-2) Envelopes Derived from Human Primary Lymphocytes. Journal of Virology, 2014, 88, 6213-6223.	1.5	43
63	IL-15 regulates susceptibility of CD4⁺T cells to HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9659-E9667.	3.3	43
64	Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. EBioMedicine, 2021, 73, 103626.	2.7	43
65	Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes. Journal of Virology, 2010, 84, 9613-9617.	1.5	42
66	The Localization of APOBEC3H Variants in HIV-1 Virions Determines Their Antiviral Activity. Journal of Virology, 2010, 84, 7961-7969.	1.5	41
67	HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle. PLoS Pathogens, 2020, 16, e1008305.	2.1	40
68	Immune mechanisms of HIV control. Current Opinion in Immunology, 2010, 22, 488-496.	2.4	38
69	Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFÎºB. Retrovirology, 2014, 11, 17.	0.9	37
70	Vif Proteins from Diverse Primate Lentiviral Lineages Use the Same Binding Site in APOBEC3G. Journal of Virology, 2013, 87, 11861-11871.	1.5	36
71	HIV-1 Infection of Primary CD4 ⁺ T Cells Regulates the Expression of Specific Human Endogenous Retrovirus HERV-K (HML-2) Elements. Journal of Virology, 2018, 92, .	1.5	34
72	The arrival and spread of SARSâ€CoVâ€2 in Colombia. Journal of Medical Virology, 2021, 93, 1158-1163.	2.5	33

#	Article	IF	Citations
73	The Resistance of Human APOBEC3H to HIV-1 NL4-3 Molecular Clone Is Determined by a Single Amino Acid in Vif. PLoS ONE, 2013, 8, e57744.	1.1	32
74	HIV Vpu Interferes with NF-ÎºB Activity but Not with Interferon Regulatory Factor 3. Journal of Virology, 2015, 89, 9781-9790.	1.5	29
75	Expression of HERV-K108 envelope interferes with HIV-1 production. Virology, 2017, 509, 52-59.	1.1	29
76	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell, 2022, 40, 441-443.	7.7	29
77	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Frontiers in Immunology, 2021, 12, 759688.	2.2	29
78	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. EBioMedicine, 2022, 80, 104073.	2.7	28
79	A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1629-1634.	1.9	27
80	Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter. Virology, 2011, 418, 57-66.	1.1	26
81	Balancing Selection on a Regulatory Region Exhibiting Ancient Variation That Predates Humanâ€“Neandertal Divergence. PLoS Genetics, 2013, 9, e1003404.	1.5	26
82	Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Vaccine, 2020, 38, 1953-1961.	1.7	25
83	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. MSphere, 2022, 7, e0017922.	1.3	25
84	Tumor Suppressor Cylindromatosis (CYLD) Controls HIV Transcription in an NF-ÎºB-Dependent Manner. Journal of Virology, 2014, 88, 7528-7540.	1.5	24
85	The Structural Interface between HIV-1 Vif and Human APOBEC3H. Journal of Virology, 2017, 91, .	1.5	24
86	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Journal of Virology, 2018, 92, .	1.5	24
87	Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection. Journal of Virology, 2004, 78, 2242-2246.	1.5	23
88	Characterization of HIV-1 integrase N-terminal mutant viruses. Virology, 2007, 360, 129-135.	1.1	22
89	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. Journal of Virology, 2019, 93, .	1.5	21
90	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Science Immunology, 2021, 6, .	5.6	20

#	Article	IF	Citations
91	Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif. Cell Cycle, 2015, 14, 838-847.	1.3	19
92	Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nature Communications, 2022, 13, .	5.8	19
93	Synthesis and anti-human immunodeficiency virus type 1 activities of new peptido-nucleoside analogues. European Journal of Medicinal Chemistry, 1995, 30, 789-800.	2.6	18
94	Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. Nature Communications, 2021, 12, 3463.	5.8	18
95	Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection In Vitro and in a Mouse Model. MSphere, 2018, 3, .	1.3	17
96	SARS-CoV-2 spread across the Colombian-Venezuelan border. Infection, Genetics and Evolution, 2020, 86, 104616.	1.0	16
97	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. MSphere, 2022, 7, .	1.3	16
98	Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase. MSphere, 2021, 6, .	1.3	15
99	Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects. MSphere, 2019, 4, .	1.3	14
100	Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. JCI Insight, 2017, 2, e88226.	2.3	14
101	ISG15 deficiency restricts HIV-1 infection. PLoS Pathogens, 2022, 18, e1010405.	2.1	14
102	Positive Regulation of TRAF6-Dependent Innate Immune Responses by Protein Phosphatase PP1-Î³. PLoS ONE, 2014, 9, e89284.	1.1	13
103	Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes. Aids, 2016, 30, 1723-1729.	1.0	13
104	Characterization of swine-origin H1N1 canine influenza viruses. Emerging Microbes and Infections, 2019, 8, 1017-1026.	3.0	13
105	FACSâ€Mediated Isolation of Neuronal Cell Populations From Virusâ€Infected Human Embryonic Stem Cellâ€“Derived Cerebral Organoid Cultures. Current Protocols in Stem Cell Biology, 2019, 48, e65.	3.0	13
106	Real-Time Investigation of a Large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology. Clinical Infectious Diseases, 2021, 73, e4375-e4383.	2.9	13
107	Synthesis of New Thiazolidinone Nucleoside Analogues. Nucleosides & Nucleotides, 1995, 14, 1379-1392.	0.5	12
108	Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein. Journal of Virology, 2019, 93, .	1.5	12

#	Article	IF	Citations
109	Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling. Cell Reports, 2022, 39, 110690.	2.9	12
110	Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain. MBio, 2022, 13, e0358021.	1.8	12
111	Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice. Journal of Virology, 2020, 94, .	1.5	11
112	Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model. Journal of Virology, 2022, 96, JVI0142121.	1.5	11
113	Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. Cancer Cell, 2022, 40, 575-577.	7.7	11
114	Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. IScience, 2021, 24, 102937.	1.9	10
115	Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Frontiers in Immunology, 2021, 12, 746447.	2.2	9
116	Robust clinical detection of SARSâ€CoVâ€2 variants by RTâ€PCR/MALDIâ€TOF multitarget approach. Journal of Medical Virology, 2022, 94, 1606-1616.	2.5	9
117	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
118	Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin. PLoS Neglected Tropical Diseases, 2021, 15, e0009327.	1.3	6
119	Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus. Nature Communications, 2021, 12, 6161.	5.8	6
120	Hotspots for SARSâ€CoVâ€2 Omicron variant spread: Lessons from New York City. Journal of Medical Virology, 2022, 94, 2911-2914.	2.5	6
121	SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia. International Journal of Infectious Diseases, 2021, 110, 410-416.	1.5	5
122	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
123	The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility. Retrovirology, 2016, 13, 64.	0.9	4
124	Reply to Hasenkrug et al., â€œDifferent Biological Activities of Specific Interferon Alpha Subtypesâ€• MSphere, 2019, 4, .	1.3	4
125	Positive, again! What to make of â€œre-positiveâ€•SARS-CoV-2 molecular test results. EBioMedicine, 2020, 60, 103011.	2.7	4
126	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. Journal of Molecular Diagnostics, 2022, , .	1.2	3

#	Article	IF	Citations
127	Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations. Frontiers in Cell and Developmental Biology, 2022, 10, 768356.	1.8	2
128	Heterogeneity of Latency Establishment in the Different Human CD4 ⁺ T Cell Subsets Stimulated with IL-15. Journal of Virology, 2022, 96, e0037922.	1.5	2
129	Development of an HIV reporter virus that identifies latently infected CD4+ TÂcells. Cell Reports Methods, 2022, 2, 100238.	1.4	2
130	Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis. Aids, 2003, 17, 2142-2143.	1.0	1
131	Contribution of APOBEC3-Driven Mutagenesis to HIV Evolution and HIV Drug Resistance. , 2017, , 41-57.		1
132	Contribution of APOBEC3-Driven Mutagenesis to HIV Evolution and HIV Drug Resistance. , 2014, , 1-15.		0
133	An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies. Vaccines, 2019, 7, 51.	2.1	0
134	Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis. Aids, 2003, 17, 2143-5.	1.0	0